The genetic complexity shown in GBM involves several genetic and epigenetic modifications that result in the loss of tumor suppressor gene function (CDKN2A/B and PTEN) or the activation of oncogenic pathways (CDK4, p21–RAS, and MDM2) [22,23,24]. The gene discussed is PTEN; the disease is glioblastoma.